Vertex Pharmaceuticals Inc. saw its shares surge 12 percent Tuesday after regulators indicated the company’s Hepatitis C drug candidate telaprevir is nearing approval. The news is expected to seal the Cambridge-based company’s planned move to Boston.
View PDF
April 24, 2011
Local firm Vertex Pharmaceuticals spent decades and billions on a pill to treat hepatitis C.
View PDFarchive.php